News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer.
The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and hopes that existing medications could slow the progression of dementia.
The top stories:
Could GLP-1 receptor agonists treat addiction and dementia?
Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia.
Early trial success for Dravet syndrome and ALS therapeutic
Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001, a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS).
Alzheimer’s immunotherapy offers safer, cheaper alternative
A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies.
NLRP3 inhibitor for neuroinflammation enters trials
The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient.
Routine vaccines as effective as antibodies against Alzheimer’s
A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD).
